Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320202 | 1.00 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL13804034 | 1.00 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL12871846 | 0.85 | UGT2B7 (0.61) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL28276305 | 0.83 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL19286311 | 0.83 | UGT2B7 (0.59) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL23742881 | 0.82 | UGT2B7 (0.62) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL15979349 | 0.82 | UGT2B7 (0.57) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL19712487 | 0.82 | UGT2B7 (0.57) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL30128757 | 0.82 | MMP9 (0.63) | UGT2B7MMP9CYP2D6MEN1CYP1A2 | |
| SCHEMBL2668985 | 0.82 | CYP1A2 (0.52) | UGT2B7MMP9CYP2D6MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535594-B2 | Microbiocidal picolinamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-12-27 | — | — | US | disclosed |
| US-20210107875-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| CN-107709309-B | Process for producing fluorine-containing cyclopropanecarboxylic acid | 中央硝子株式会社 | 2020-10-09 | — | — | CN | disclosed |
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2010168-B1 | HISTONE DEACETYLASE INHIBITORS | HARVARD COLLEGE (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8629156-B2 | Tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8410121-B2 | Methods of treating pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100280054-A1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | TERSERA THERAPEUTICS LLC | 2010-11-04 | — | — | US | disclosed |
| US-7723345-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7713961-B2 | Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TERSERA THERAPEUTICS LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2009-01-01 | — | — | US | disclosed |
| WO-2008091349-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TPH1, PAH, TPH2 | UGT2B7 1030/4885MMP9 1245/4885CYP2D6 305/4885 |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | TPH1, TPH2, PTGIS | UGT2B7 1467/4885MMP9 1194/4885CYP2D6 446/4885 |
| US-20100280054-A1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | AADAT, HNMT, TPH1 | UGT2B7 321/4885MMP9 2687/4885CYP2D6 165/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | UGT2B7 321/4885MMP9 2687/4885CYP2D6 165/4885 |
| US-11535594-B2 | Microbiocidal picolinamide derivatives | PRF1, CASP1, FPR1 | UGT2B7 1926/4885MMP9 1684/4885CYP2D6 417/4885 |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | TPH1, TPH2, IDO1 | UGT2B7 2190/4885MMP9 111/4885CYP2D6 217/4885 |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | PSEN1, PSEN2, BACE1 | UGT2B7 1333/4885MMP9 3632/4885CYP2D6 721/4885 |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | TPH1, TPH2, HNMT | UGT2B7 886/4885MMP9 2062/4885CYP2D6 429/4885 |
| US-20210107875-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | PRF1, CASP1, FPR1 | UGT2B7 1926/4885MMP9 1684/4885CYP2D6 417/4885 |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, HNMT | UGT2B7 253/4885MMP9 1006/4885CYP2D6 126/4885 |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, MAOB | UGT2B7 154/4885MMP9 1336/4885CYP2D6 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.